<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02238223</url>
  </required_header>
  <id_info>
    <org_study_id>262.290</org_study_id>
    <nct_id>NCT02238223</nct_id>
  </id_info>
  <brief_title>Postmarketing Surveillance to Investigate the Safety and Efficacy Information of Alesion® Tablet</brief_title>
  <official_title>Post Marketing Surveillance of Alesion® (Epinastine Hydrochloride) Tablet</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Study to investigate the safety and efficacy information of Alesion® Tablet under the proper
      use in daily clinical practice after new treatment guideline for allergic rhinitis, bronchial
      asthma, eczema, dermatitis, urticaria, pruritus, prurigo and psoriasis vulgaris with itching
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2004</start_date>
  <primary_completion_date type="Actual">May 2006</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse drug reactions</measure>
    <time_frame>up to 24 months</time_frame>
    <description>classified by Medical Dictionary for Regulatory Activities (MedDRA)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of adverse drug reactions classified by patient's background/treatment factors</measure>
    <time_frame>up to 24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall assessment of efficacy by investigator on a 3-point scale</measure>
    <time_frame>after 24 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">2001</enrollment>
  <condition>Rhinitis, Allergic, Perennial</condition>
  <arm_group>
    <arm_group_label>Patients without experience in treatment with epinastine</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alesion®</intervention_name>
    <arm_group_label>Patients without experience in treatment with epinastine</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients without experience treating of epinastine are selected by physicians at medical
        institutions
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All the patients who:

          -  haven't treatment experience of epinastine product;

          -  have at least one out of following diseases. allergic rhinitis, eczema, dermatitis,
             pruritus, prurigo, urticaria, psoriasis with itching, bronchial asthma

        Exclusion Criteria:

          -  Alesion® Tablet is contraindicated for the patients with history of hypersensitivity
             to any ingredients of Alesion® Tablet in package insert. However, it is unknown
             whether a patient is hypersensitive to the ingredients of the product in almost cases.
             And this survey is drug utilization study to observe actual use in any patients.
             Therefore exclusion criteria is not set in the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 11, 2014</study_first_submitted>
  <study_first_submitted_qc>September 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2014</study_first_posted>
  <last_update_submitted>September 11, 2014</last_update_submitted>
  <last_update_submitted_qc>September 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 12, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis, Allergic, Perennial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epinastine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

